TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | MicrobiomeTrials← Back to trialsNCT04485013
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2020-07-14Est. Completion: 2027-06-01
Enrollment target: 240 participants Locations- Arizona Oncology Associates, Tucson, Arizona, United States
- University of Southern California, Los Angeles, California, United States
- Hoag Memorial Hospital, Newport Beach, California, United States
- Rocky Mountain Cancer Centers, Denver, Colorado, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Christiana Care Helen F. Graham Cancer Center, Newark, Delaware, United States
- John Hopkins Kimmer Cancer Center, Washington D.C., District of Columbia, United States
- Florida Cancer Specialists, Daytona Beach, Florida, United States
- Florida Cancer Specialists, Fleming Island, Florida, United States
- Ocala Oncology Center, Ocala, Florida, United States
- AdventHealth Research Institute, Orlando, Florida, United States
- Illinois Cancer Specialists, Arlington Heights, Illinois, United States
- University of Illinois, Chicago, Illinois, United States
- Indiana University, Indianapolis, Indiana, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- American Oncology Partners, P.A. - The Center for Cancer & Blood Disorders, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Oesophageal Squamous Cell CarcinomaOesophageal AdenocarcinomaGastric AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)CholangiocarcinomaHepatocellular Carcinoma (HCC)Colorectal Adenocarcinoma
The investigators of this study are developing a simple breath test to help detect gastrointestinal (gut) cancers earlie…
Maidstone, United KingdomEst. completion Feb 2, 2028
Advanced Solid Tumor
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary …
Maryland Oncology Hematology, Silver Spring, Maryland, United StatesDana-Farber Cancer Institute, Boston, Massachusetts, United StatesSTART Midwest, Grand Rapids, Michigan, United StatesRegions Hospital Cancer Care Center, Saint Paul, Minnesota, United StatesWashington University in St Louis, St Louis, Missouri, United StatesNebraska Cancer Center Oncology Hematology West P.C., Omaha, Nebraska, United StatesRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United StatesIcahn School of Medicine at Mount Sinai, New York, New York, United StatesStony Brook University, Stony Brook, New York, United StatesUniversity of Cincinnati, Cincinnati, Ohio, United StatesZangmeister Cancer Center, Columbus, Ohio, United StatesThe University of Toledo, Toledo, Ohio, United StatesUniversity of Oklahoma, Oklahoma City, Oklahoma, United StatesUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United StatesMedical University of South Carolina, Charleston, South Carolina, United StatesSarah Cannon Research Institute, Nashville, Tennessee, United StatesVanderbilt - Ingram Cancer Center, Nashville, Tennessee, United StatesTexas Oncology - Dallas, Dallas, Texas, United StatesSTART Dallas, Fort Worth, Texas, United StatesThe University of Texas MD Anderson Cancer Center, Houston, Texas, United StatesTexas Oncology - Paris, Paris, Texas, United StatesNEXT Oncology, San Antonio, Texas, United StatesNEXT Oncology Virginia, Fairfax, Virginia, United StatesNorthwest Medical Specialties, Tacoma, Washington, United StatesNorthwest Cancer Specialists, Vancouver, Washington, United StatesBirmingham, United StatesEst. completion Nov 1, 2028
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to ass…
Duarte, United StatesEst. completion Jul 2027